The sterling pharmaceutical services eyedrop recall affects 747,844 ophthalmic products sold across the United States, including more than 500,000 Walgreens-branded lubricant eye-drop units. Sterling Pharmaceutical Services LLC began the voluntary recall on August 20, 2026, after concerns about sterility assurance during manufacturing.
The affected products include lubricating eye drops, a hypertonicity eye solution and a nighttime ophthalmic ointment. They were marketed under several brand names and distributed nationwide.
The recall became a Class II action on September 21, 2026. Consumers with affected products should stop using them and check the product and lot information carefully.
Why the Eye Products Were Recalled
Sterility is a critical requirement for products placed directly into the eyes. The recall followed observations involving manufacturing and aseptic-processing controls at Sterling Pharmaceutical Services.
The company has stated in recall notices that it had not identified confirmed sterility failures or evidence of product contamination in the affected products. The action was taken as a precaution because the manufacturing observations could affect confidence in the products’ sterility.
That distinction is important. The recall does not establish that every affected bottle or tube is contaminated.
However, consumers should not attempt to judge sterility by looking at a product. A clear solution or intact container does not prove that an ophthalmic product meets sterile manufacturing requirements.
How Large Is the Recall?
The recall covers nine ophthalmic product entries and 747,844 units.
The affected products include:
- Cameron Pharmaceuticals Carboxymethylcellulose Sodium 0.5% Eye Lubricant — 19,284 units
- AvKare Carboxymethylcellulose Sodium Ophthalmic Solution 0.5% — 12,864 units in one package configuration
- AvKare Carboxymethylcellulose Sodium Ophthalmic Solution 0.5% — 107,377 units in another package configuration
- Reliable-1 Laboratories Sodium Chloride Hypertonicity Ophthalmic Solution 5% — 11,083 units
- Reliable-1 Laboratories Lubricating Tears — 47,616 units
- Walgreens Lubricant Eye Drops — 301,114 individual bottles
- Walgreens Lubricant Eye Drops — 199,600 twin packs
- TRP The Relief Products Gentle Eyes Lubricant Eye Drops — 14,538 units
- Major LubriFresh P.M. Nighttime Ointment — 34,368 units
The combined number reaches 747,844 recalled units.
Walgreens Products Make Up the Largest Share
Walgreens-branded lubricant eye drops account for the biggest portion of the recall.
The affected inventory includes 301,114 individual bottles and 199,600 twin packs. Together, those products represent 500,714 units.
The affected lubricant drops contain carboxymethylcellulose sodium 0.5% and are intended to provide temporary relief from dry-eye symptoms, including burning, irritation and discomfort.
Consumers should not assume that every Walgreens lubricant eye drop is affected. The recall applies to specified products and production lots.
Checking the package details is therefore more important than relying solely on the retailer’s name.
Other Products Included
Several other brands are part of the same manufacturing-related recall.
AvKare products include carboxymethylcellulose sodium ophthalmic solution 0.5%, marketed as lubricant eye drops. Both individual and twin-pack configurations are included.
Reliable-1 Laboratories products involved in the action include Lubricating Tears and a 5% sodium chloride hypertonicity ophthalmic solution.
The recall also covers Cameron Pharmaceuticals Carboxymethylcellulose Sodium 0.5% Eye Lubricant, TRP The Relief Products Gentle Eyes Lubricant Eye Drops and Major LubriFresh P.M. Nighttime Ointment.
Because these products have different labels and intended uses, consumers should identify the exact product before determining whether it is affected.
What Class II Means for Consumers
The recall received a Class II classification on September 21, 2026.
A Class II classification generally applies when exposure to a recalled product could result in temporary or medically reversible health consequences. It can also apply when the likelihood of serious adverse health effects is considered remote.
The classification does not mean that consumers are expected to suffer serious injury from using the affected products.
At the same time, consumers should not dismiss the recall. Ophthalmic products have direct contact with the eyes, making appropriate manufacturing controls especially important.
Anyone who has a recalled product should follow the recommended recall action rather than continuing to use it.
How to Check Eye Drops at Home
Consumers who have eye drops or ophthalmic ointment at home can begin by examining the package.
Important identifying information can include:
- Product name
- Brand
- Package size
- Lot number
- Expiration date
- National Drug Code, when listed
The exact combination of these details determines whether a particular product falls within the recall.
This is especially important because several of the affected products have similar names or ingredients. A product from one of the brands involved in the recall is not automatically recalled simply because it carries that brand’s name.
If the product and lot match the recalled information, consumers should discontinue use.
What Consumers Should Do With an Affected Product
Anyone who discovers a recalled product should stop using it.
Consumers who regularly depend on lubricating eye drops may want to speak with a pharmacist or healthcare professional about selecting an alternative product.
People who develop unusual or concerning eye symptoms after using an affected product should seek medical advice.
Consumers should also avoid giving a recalled product to another person. A product that is unsuitable for one household should not be passed to family members, friends or other users.
The recall applies regardless of whether the product appears normal.
Why Ophthalmic Sterility Matters
The eyes have natural protective mechanisms, but medications and other products placed directly into the eye can bypass some of those defenses.
For that reason, ophthalmic products must be manufactured under appropriate sterile conditions.
A failure to maintain adequate sterility assurance can create a potential pathway for microorganisms to reach the eye. Depending on the circumstances, an eye infection can cause symptoms ranging from irritation to more serious complications.
That is why a sterility-related recall deserves attention even when no confirmed contamination has been identified in the affected products.
The Recall Does Not Cover Every Sterling Product
Consumers should avoid interpreting the recall as a blanket warning against all products manufactured by Sterling Pharmaceutical Services.
The current action concerns specifically identified ophthalmic products and lots.
Likewise, the presence of Walgreens, AvKare, Reliable-1 Laboratories or another affected brand on a package does not automatically mean the product belongs to the recalled inventory.
The lot information remains essential.
This approach can help consumers avoid discarding unaffected products while ensuring recalled products are removed from use.
Current Status of the Recall
As of October 5, 2026, the recall remains active and involves 747,844 ophthalmic product units.
The action began on August 20 and was classified as Class II on September 21. The affected products remain tied to concerns over the assurance of sterility during manufacturing.
The Walgreens portion is particularly significant because it represents 500,714 units, but consumers should also check products sold under the other affected brand names.
The most reliable way to determine whether an item is involved is to compare its complete identifying information with the current recall listing.
For households that regularly use artificial tears, lubricating drops or ophthalmic ointments, checking medicine cabinets and recently purchased products can help ensure that recalled items are not accidentally used.
What to Remember About the Recall
The key facts are straightforward. Sterling Pharmaceutical Services initiated the recall after manufacturing and aseptic-processing concerns raised questions about sterility assurance.
A total of 747,844 units across nine ophthalmic product entries are affected. More than 500,000 of those units carry the Walgreens name.
The recall does not establish that every affected product is contaminated. Instead, the products were recalled because sterility could not be adequately assured.
Consumers should identify the exact product and lot number, discontinue use if the item is included, and seek professional medical guidance if they have concerns about symptoms or replacement treatment.
Consumers with eye drops at home should check the product details carefully and take action if their package matches the recalled lots.